Intellinetics (INLX) Q2 2026 Earnings Call Transcript

Intellinetics (INLX) reported Q2 2026 earnings with SaaS revenue up 4.2% YoY to $1.6M, but total revenue down 1.6% to $3.9M due to lower professional services. CEO Alison Forsythe highlighted improvements in software bookings, pipeline strength, and operational changes. Net loss widened to $1.1M from $600K YoY, with adjusted EBITDA at $331K.

Original reporting
Published Aug 20, 2026, 12:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 12:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Intellinetics (INLX) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$INLXBearishMed
01

Why it matters

The earnings release provides fresh guidance and performance metrics that were not previously public.

02

Market read

First disclosure of Q2 2026 results for a micro‑cap SaaS transition company; relevant for traders tracking earnings of small‑cap tech firms.

03

What to watch

The decline in professional services is cyclical; the new website and pipeline improvements could accelerate future bookings.

Relevance 6/10Novelty 7/10Timing: Q2 2026 earnings release

Background

Intellinetics is a micro‑cap software and services company transitioning to a SaaS‑focused model.

Company-level read

Ticker impact

$INLXBearishMedium confidence
Context

Intellinetics reported Q2 2026 results, including a 1.6% revenue decline to $3.9M and a net loss of $1.1M.

Expected impact

Potential short‑term downside with a longer‑term upside if SaaS growth materializes.

Evidence & confidence

Loss widening and revenue dip are negative, but management’s focus on recurring SaaS revenue and operating leverage offers a catalyst for future improvement.

Market effects

Highlights challenges for small SaaS and document‑services firms in balancing professional services decline with SaaS growth.

Primarily U.S. micro‑cap investors; limited broader regional effect.

Low global impact; relevant to niche SaaS and document‑automation niche.

Counterpoint

Despite the loss, the company’s low base may allow rapid scaling of SaaS revenue, making it a potential turnaround play.

Key entities

  • Alison Forsythe

    President and CEO of Intellinetics, presented the earnings commentary.

  • Joseph D. Spain

    Chief Financial Officer, presented the financial details.

Related articles

$INLXMed

Intellinetics Reports Second Quarter and Six-Month 2026 Results

INTELLINETICS, INC. (INLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellinetics Reports Second Quarter and Six-Month 2026 Results COLUMBUS, OH – August 12, 2026 – Intellinetics, Inc. ( NYSE American: INLX ), a digital transformation solutions provider, announced financial results for the three and six months ended June 30, 2026. 20

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.